These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1118 related articles for article (PubMed ID: 32277821)
1. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821 [TBL] [Abstract][Full Text] [Related]
2. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343 [TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986 [TBL] [Abstract][Full Text] [Related]
6. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ; J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital. Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain. Cercenado E; Cardenoso L; Penin R; Longshaw C; Henriksen AS; Pascual A J Glob Antimicrob Resist; 2021 Sep; 26():292-300. PubMed ID: 34274538 [TBL] [Abstract][Full Text] [Related]
10. Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291 [TBL] [Abstract][Full Text] [Related]
11. Activity of Cefiderocol Against Iregui A; Khan Z; Landman D; Quale J Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany. Kresken M; Korte-Berwanger M; Gatermann SG; Pfeifer Y; Pfennigwerth N; Seifert H; Werner G Int J Antimicrob Agents; 2020 Oct; 56(4):106128. PubMed ID: 32758648 [TBL] [Abstract][Full Text] [Related]
15. Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F; Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963 [TBL] [Abstract][Full Text] [Related]
16. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa. Delgado-Valverde M; Portillo-Calderón I; Alcalde-Rico M; Conejo MC; Hidalgo C; Del Toro Esperón C; Pascual Á Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):445-457. PubMed ID: 38157139 [TBL] [Abstract][Full Text] [Related]
18. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018. Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]